TUDCA (tauroursodeoxycholic acid) is a water-soluble bile acid that protects cells from stress-related damage throughout the body. It occurs naturally in small amounts in human bile and has been used therapeutically in traditional Chinese medicine for centuries. In modern research, TUDCA has shown measurable benefits for liver function, insulin sensitivity, and neurological health, with clinical trials now testing it against serious degenerative diseases.
How TUDCA Works Inside Cells
Your cells contain a structure called the endoplasmic reticulum, essentially a protein-folding factory. When this factory gets overwhelmed, proteins misfold and accumulate, triggering a stress response that can spiral into cell death. TUDCA acts as a chemical chaperone, stabilizing proteins and helping them fold correctly, which prevents this destructive cascade before it starts.
More specifically, TUDCA blocks a calcium-driven pathway that leads to programmed cell death. When cells are under stress, calcium floods out of the endoplasmic reticulum and activates a chain of enzymes (called caspases) that dismantle the cell from the inside. TUDCA reduces this calcium release and shuts down the caspase activation that follows. In lab studies, it abolished the markers of endoplasmic reticulum stress almost entirely. This mechanism is central to nearly every benefit researchers have observed, because endoplasmic reticulum stress plays a role in liver disease, neurodegeneration, metabolic dysfunction, and retinal damage.
Protecting the Liver
TUDCA’s longest-established use is in liver health, particularly for cholestatic conditions where bile flow is impaired. When bile can’t drain properly, toxic hydrophobic bile acids accumulate inside liver cells, promoting injury, scarring, and eventually cirrhosis. TUDCA works by replacing these harmful bile acids with a more water-soluble alternative, shifting the overall bile acid pool toward a less toxic composition. It also lowers levels of specific damaging bile acids in both the blood and digestive tract.
In a randomized, double-blind trial of patients with primary biliary cholangitis, about 76% of those taking TUDCA achieved a greater than 25% reduction in alkaline phosphatase (a key marker of bile duct damage) after 24 weeks. More than half saw reductions exceeding 40%. These results were comparable to UDCA, the current standard treatment, which makes sense given that TUDCA is actually the taurine-conjugated form of UDCA and its primary active metabolite in the body. The taurine attachment makes TUDCA more water-soluble, which may allow it to clear toxic bile acids more efficiently.
Improving Insulin Sensitivity
A clinical trial at Washington University gave obese adults 1,750 mg of TUDCA daily for four weeks and measured how their bodies responded to insulin. The results were striking: liver insulin sensitivity improved by roughly 30%, and muscle glucose uptake increased by about 34% compared to pre-treatment levels. The placebo group saw no change in either measure.
At the molecular level, TUDCA enhanced insulin signaling in muscle tissue by increasing the activation of two key proteins in the insulin response pathway. This means muscle cells became better at recognizing and responding to insulin’s signal to absorb glucose from the blood. One limitation: TUDCA did not improve insulin sensitivity in fat tissue. The effect appears specific to the liver and muscles, which are the two organs most responsible for clearing glucose from your bloodstream after a meal.
Slowing Neurological Decline
The most dramatic clinical findings for TUDCA come from trials in amyotrophic lateral sclerosis (ALS). In a placebo-controlled study where ALS patients took 2 grams of TUDCA daily alongside standard treatment, the rate of functional decline slowed significantly. Patients on TUDCA lost an average of 1.13 points per month on a standard functional rating scale, compared to 1.60 points per month for placebo. By the end of the study, the TUDCA group scored 7 points higher overall, a clinically meaningful gap. The response rate was also lopsided: 87% of TUDCA patients were classified as responders versus 43% on placebo.
A separate trial combined TUDCA with sodium phenylbutyrate (another compound that reduces cellular stress) and found similar functional benefits, plus a survival advantage. Patients on the combination lived a median of 25.8 months compared to 18.9 months for placebo, representing a 43% lower risk of death over the treatment period. A follow-up analysis estimated the survival benefit could be as large as 10.6 additional months.
Beyond ALS, TUDCA has shown neuroprotective effects in animal models of Alzheimer’s and Parkinson’s disease, where it reduces endoplasmic reticulum stress in brain tissue. These remain preclinical findings, but the mechanism is consistent with what’s been observed in human ALS trials: TUDCA helps cells survive the protein misfolding and cellular stress that drive neurodegeneration.
Protecting the Eyes
Photoreceptors, the light-sensing cells in your retina, are particularly vulnerable to oxidative damage and cellular stress. In experimental models of retinal detachment, TUDCA protected photoreceptors by inhibiting the caspase enzymes that trigger cell death and by nearly eliminating the buildup of reactive oxygen species (a measure of oxidative damage). These protective effects are relevant to several conditions that threaten vision: retinal detachment, age-related macular degeneration, diabetic retinopathy, and retinitis pigmentosa. The research here is largely preclinical, but the consistent results across multiple retinal disease models suggest TUDCA’s cell-protective mechanism translates well to eye tissue.
TUDCA vs. UDCA
If you’ve come across UDCA (ursodeoxycholic acid), you might wonder how it differs from TUDCA. UDCA is the parent compound. When you take UDCA orally, your body converts much of it into TUDCA by attaching a taurine molecule. TUDCA is therefore more water-soluble than UDCA, which in theory allows it to integrate into the bile acid pool more effectively and may explain subtle differences in how the two are absorbed. In clinical trials for liver disease, their efficacy has been roughly equivalent. The choice between them often comes down to availability and formulation, since UDCA is an established prescription medication while TUDCA is more commonly found as a supplement.
Dosages Used in Clinical Trials
Human studies have used TUDCA at different doses depending on the condition. For ALS, the standard dose has been 1 gram twice daily (2 grams total per day), taken for periods ranging from 54 weeks to several years. The insulin sensitivity trial used 1,750 mg per day for four weeks. These are the doses with published evidence behind them. Supplement manufacturers typically sell TUDCA in capsules of 250 to 500 mg, with suggested servings well below what’s been used in clinical research.
Side Effects and Safety
TUDCA is generally well tolerated. In a controlled trial tracking adverse events, side effects occurred at similar rates in the TUDCA and placebo groups (38% vs. 33%). The most common complaints were gastrointestinal: diarrhea affected about 12% of TUDCA users, followed by nausea, indigestion, and abdominal cramps at roughly 8% each. One participant developed a facial rash.
The one serious event reported was a case of cholangitis (bile duct inflammation) in a participant taking TUDCA, though the safety monitoring board deemed it unlikely to be caused by the supplement. Still, researchers noted this highlights the importance of caution for anyone with abnormal bile duct anatomy or a history of biliary disease. Clinical trials have also excluded people with prior liver disease, severe kidney disease, and those who are pregnant or nursing.